[{"NetIncomeLoss_1_Q2_USD":-26095000.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":72558000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":72558000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":17.77,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1901.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":1000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_2_Q2_USD":0.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":7145000.0,"AssetsCurrent_0_Q2_USD":211355000.0,"OtherNoncashIncomeExpense_2_Q2_USD":1000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":2535000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":6154000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":52340000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":802000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":55153000.0,"CommonStocksIncludingAdditionalPaidInCapital_0_Q2_USD":418040000.0,"CommonStockSharesIssued_0_Q2_shares":37688000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":24991000.0,"Assets_0_Q2_USD":216929000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-15000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-9000.0,"ShareBasedCompensation_2_Q2_USD":7639000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":2069000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":72558000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":745000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q2_USD":33246000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":10000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0_Q2_USD":14.77,"ResearchAndDevelopmentExpense_1_Q2_USD":20487000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":14.77,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":1901000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":73360000.0,"DeferredCompensationLiabilityClassifiedNoncurrent_0_Q2_USD":12000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2_Q2_USD":0.0,"RestrictedCash_0_Q2_USD":500000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":203800000.0,"OtherAssetsCurrent_0_Q2_USD":1121000.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_2_Q2_USD":0.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-49011000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-26104000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":178771000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":3558000.0,"Liabilities_0_Q2_USD":15489000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-15000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-9000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q2_USD":12.27,"DepreciationAndAmortization_2_Q2_USD":454000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":10936000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":5602000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":35048000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":37061000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ResearchAndDevelopmentExpense_2_Q2_USD":38071000.0,"InterestReceivableCurrent_0_Q2_USD":113000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":941000.0,"RestrictedCashNoncurrent_0_Q2_USD":500000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q2_shares":6145.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":11000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":7639000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":4233000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-40016000.0,"LiabilitiesCurrent_0_Q2_USD":11919000.0,"NonoperatingIncomeExpense_2_Q2_USD":11000.0,"NonoperatingIncomeExpense_1_Q2_USD":-6000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":179271000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7593000.0,"CommonStockSharesOutstanding_0_Q2_shares":37680000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":802000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q2_Security":0.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":62.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":522000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":522000.0,"NumberOfOperatingSegments_2_Q2_Segment":1.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_2_Q2_USD":0.0,"PrepaidInsurance_0_Q2_USD":166000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q2_USD":21138000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3005000.0,"NetIncomeLoss_2_Q2_USD":-48996000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0_Q2_USD":33246000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":85684000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-216610000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":2575.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"OperatingIncomeLoss_2_Q2_USD":-49007000.0,"OperatingIncomeLoss_1_Q2_USD":-26089000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_Q2_USD":400000.0,"InvestmentIncomeInterest_2_Q2_USD":53000.0,"InvestmentIncomeInterest_1_Q2_USD":23000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":15.71,"PreferredStockValue_0_Q2_USD":null,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":12.96,"LiabilitiesAndStockholdersEquity_0_Q2_USD":216929000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":7639000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":4233000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":39900000.0,"OperatingExpenses_2_Q2_USD":49007000.0,"OperatingExpenses_1_Q2_USD":26089000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.4,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.7,"OtherLiabilitiesCurrent_0_Q2_USD":886000.0,"StockholdersEquity_0_Q2_USD":201440000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":278000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":24981000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-170000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":6145.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":11.31,"ShortTermInvestments_0_Q2_USD":24991000.0,"Ticker":"CRNX","CIK":"1658247","name":"CRINETICS PHARMACEUTICALS, INC.","OfficialName":"Crinetics Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1104302360.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210810"}]